The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
Open accessPublished version of a preprint
Abstract
Functional and lasting immune responses to the novel coronavirus (SARS-CoV-2) are currently under intense investigation as antibody titers in plasma have been shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we sought to determine the presence of SARS-CoV-2-specific memory B cells in COVID-19 convalescent patients. In this study, we report on the evolution of the overall humoral immune responses on 101 blood samples obtained from 32 COVID-19 convalescent patients between 16 and 233 days post-symptom onset. Our observations indicate that anti-Spike and anti-RBD IgM in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity in convalescent plasma declines rapidly compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which increase over time, and the number of IgG+ memory B cells which remain stable thereafter for up to 8 months after symptoms onset. With the recent approval of highly effective vaccines for COVID-19, data on the persistence of immune responses are of central importance. Even though overall circulating SARS-CoV-2 Spike-specific antibodies contract over time during convalescence, we demonstrate that RBD-specific B cells increase and persist up to 8 months post symptom onset. We also observe modest increases in RBD-specific IgG+ memory B cells and importantly, detectable IgG and sustained Fc-effector activity in plasma over the 8-month period. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for the prevention of secondary infections, vaccine efficacy and herd immunity against COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 2×
“Similarly, recent studies 213 on the durability of SARS-CoV-2 immune responses have shown that although antibody levels 214 decrease, Spike-specific IgG+ memory B cell responses are generated and maintained (1, 5, 6).”
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · cited 1×
“Longitudinal data from a larger sample size with varying clinical symptoms ranging from asymptomatic to critical cases as well as individuals below 20 years and over 65 years of age would be required for a more precise understanding of the overall immune durability against COVID-19.”
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · cited 1×
“preventing infection in animal models (10, 23, 24).”
Research works printed but not linked: 22
- Wheatley, 2021, Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19, Nat. Commun., 12, 1162, 10.1038/s41467-021-21444-5 · DOI · Paper page
- Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
- Perreault, 2020, Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset, Blood, 136, 2588, 10.1182/blood.2020008367 · DOI
- Prévost, 2020, Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike, Cell Rep. Med., 1, 100126, 10.1016/j.xcrm.2020.100126 · DOI · Paper page
- Pradenas, 2021, Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes, Med (N Y), 2, 313
- Chan, 2020, The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody, bioRxiv
- Anand, 2021, High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples, Transfusion, 10.1111/trf.16318 · DOI
- Rojas, 2020, Convalescent plasma in Covid-19: Possible mechanisms of action, Autoimmun. Rev., 19, 102554, 10.1016/j.autrev.2020.102554 · DOI · Paper page
- Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, 324, 460, 10.1001/jama.2020.10044 · DOI · Paper page
- Devasenapathy, 2020, Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis, CMAJ, 192, E745, 10.1503/cmaj.200642 · DOI
- Klingler, 2020, Role of IgM and IgA antibodies in the neutralization of SARS-CoV-2, medRxiv
- Gasser, 2021, Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2, Cell Rep., 34, 108790, 10.1016/j.celrep.2021.108790 · DOI
- Sterlin, 2021, IgA dominates the early neutralizing antibody response to SARS-CoV-2, Sci. Transl. Med., 13, eabd2223, 10.1126/scitranslmed.abd2223 · DOI · Paper page
- Chen, 2020, Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19, Signal Transduct. Target. Ther., 5, 180, 10.1038/s41392-020-00301-9 · DOI · Paper page
- Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity, Nat. Commun., 11, 4704, 10.1038/s41467-020-18450-4 · DOI · Paper page
- Abu-Raddad, 2021, SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks, medRxiv
- Natarajan, 2020, SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy, medRxiv
- Ullah, 2021, Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy, bioRxiv
- Brunet-Ratnasingham, 2021, Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality, medRxiv
- ter Meulen, 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med., 3, e237, 10.1371/journal.pmed.0030237 · DOI · Paper page
- Liu, 2013, The interferon-inducible MxB protein inhibits HIV-1 infection, Cell Host Microbe, 14, 398, 10.1016/j.chom.2013.08.015 · DOI · Paper page
- Lodge, 1997, The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells, EMBO J., 16, 695, 10.1093/emboj/16.4.695 · DOI · Paper page
Cited by
Bégin, P., Callum, J., Jamula, E., Cook, R., Heddle, N. M., Tinmouth, A., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01488-2 · Cited by 258
Self-citationInfection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann, A., Planchais, C., Buchrieser, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100275 · Cited by 89
Mandolo, J., Msefula, J., Henrion, M. Y. R., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02187-y · Cited by 61
“Second, in some individuals, SARS-CoV-2 antibodies wane over time to undetectable levels leading to false negatives, especially in those who had asymptomatic COVID-19 [27, 28].”
BackgroundShen, A.-R., Jin, X.-X., Tang, T.-T., Ding, Y., Liu, X.-T., Zhong, X., Wu, Y.-D., Han, X.-L., Zhao, G.-Y., Shen, C.-L., et al. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s367494 · Cited by 19
Metadata
- Authors
- Anand, S. P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S. Y., Bourassa, C., Brunet-Ratnasingham, E., Medjahed, H., Gendron-Lepage, G., Goyette, G., Gokool, L., Morrisseau, C., Bégin, P., Martel-Laferrière, V., Tremblay, C., Richard, J., Bazin, R., Duerr, R., Kaufmann, D. E., & Finzi, A.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 2
- Issue
- 6
- Pages
- 100290
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W3159965848
- Cited by
- 175
- References
- 24
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Institutes of Health (R01 AI122953-05)
- National Institute of Allergy and Infectious Diseases (ARP-4376)
- American Foundation for Aging Research
- Fondation du CHUM
- CHU Sainte-Justine Foundation
- Fonds de Recherche du Québec - Santé
- Canada Foundation for Innovation (41027, RCHS0235 950-232424)
- Mitacs
- Canadian Institutes of Health Research (VR2-173203)
- CIHR III (352417)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. https://app.cochat.ai/papers/10.1016/j.xcrm.2021.100290
- The paper
- Anand, S. P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S. Y., Bourassa, C., Brunet-Ratnasingham, E., Medjahed, H., Gendron-Lepage, G., Goyette, G., Gokool, L., Morrisseau, C., Bégin, P., Martel-Laferrière, V., Tremblay, C., . . . Finzi, A. (2021). Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.